Clinical trials: Hemoperfusion

Septic Shock, Endotoxemia

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock

• Completed
• Age: 18 years and older
• Medical device
• Results posted

To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge…

Trial name

EUPHRATES (NCT01046669)

Testing

TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock

Where

40 sites in United States, Canada

Volunteers

450 people

Sponsor

Spectral Diagnostics (US) Inc.